Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses.
Hypothesis: RT-CGM provided to young adults with suboptimal blood glucose control, has a beneficial impact on HbA1c and hospital admissions for high blood glucoses. We will use data from this pilot work to inform a larger powered study to address this knowledge gap.
Adolescents and young adults aged 18-25 years
Insulin-treated diabetes >12 months (on multiple daily injections or insulin pump therapy)
HbA1c > 75 mmol/mol (9%) or 1 or more DKA admissions in the last 12 months or 1 or more admissions with uncontrolled blood glucose levels in the last 12 months.
Naïve to RT-CGM - except for short periods for use for diagnosis or monitoring purposes.
Chronic kidney disease eGFR <30ml/min
Pregnant or planning pregnancy
Breastfeeding
Have active malignancy or under investigation for malignancy
Crossover
Dexcom G6
DeviceRealtime Continous Glucose Monitoring
Self monitoring of blood glucose
DeviceFinger prick self monitoring of blood glucose
Change in glycated haeomglobin (HbA1c)
Change over intervention period or standard care (control) period, with each participant acting as their own control
Click on the lead sponsor to view all of their trials.
Imperial College London
Lead sponsor
DexCom, Inc.
Collaborator
